Compare Lumen Technologies Inc (LUMN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Summit Therapeutics Inc — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Lumen Technologies Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Summit Therapeutics Inc for 16 Days on average.
| LUMN | SMMT | |
|---|---|---|
Market Cap | $5.73B | $13.71B |
Volume | 17,079,799 | 6,173,057 |
Sector | Media | Health |
52-Week High | $11.83 | $26.38 |
52-Week Low | $5.53 | $12.43 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | $17.35B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.28, down 10.66% in the last session, reflecting ongoing investor concerns. The stock shows bearish technical signals with mixed earnings performance - beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Despite revenue declining from $17.5B in 2022 to $12.4B in 2025, the company maintains strong operating cash flow of $4.7B and is strategically pivoting toward AI networking services.
LUMN presents a high-risk turnaround opportunity with significant debt burden ($17.5B long-term) and negative profitability metrics. The AI-focused strategy shows promise but faces execution risk against steep legacy revenue declines. Analyst consensus remains cautious with 61% hold ratings, suggesting investors await concrete evidence of sustainable growth before committing.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
